CT-P13 is a chimeric human–murine IgG1 monoclonal antibody biosimilar to infliximab (Remicade). It is an anti–TNF-α mAb that binds soluble and transmembrane TNF-α, blocking TNFR1/TNFR2 signaling, reducing NF-κB/MAPK pathway activation and downstream pro‑inflammatory cytokines (e.g., IL‑1, IL‑6) and adhesion molecules; it can induce apoptosis and CDC/ADCC against TNF‑expressing cells. Administered intravenously (IV) or subcutaneously (SC).